These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 9450621)
1. The effects of levosimendan on [Ca2+]i in guinea-pig isolated ventricular myocytes. Lancaster MK; Cook SJ Eur J Pharmacol; 1997 Nov; 339(1):97-100. PubMed ID: 9450621 [TBL] [Abstract][Full Text] [Related]
2. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Edes I; Kiss E; Kitada Y; Powers FM; Papp JG; Kranias EG; Solaro RJ Circ Res; 1995 Jul; 77(1):107-13. PubMed ID: 7788868 [TBL] [Abstract][Full Text] [Related]
3. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. Sato S; Talukder MA; Sugawara H; Sawada H; Endoh M J Mol Cell Cardiol; 1998 Jun; 30(6):1115-28. PubMed ID: 9689586 [TBL] [Abstract][Full Text] [Related]
4. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition. Kaheinen P; Pollesello P; Hertelendi Z; Borbély A; Szilágyi S; Nissinen E; Haikala H; Papp Z Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):74-8. PubMed ID: 16433895 [TBL] [Abstract][Full Text] [Related]
5. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Haikala H; Kaheinen P; Levijoki J; Lindén IB Cardiovasc Res; 1997 Jun; 34(3):536-46. PubMed ID: 9231037 [TBL] [Abstract][Full Text] [Related]
6. The cardiotonic effects of levosimendan in guinea pig hearts are modulated by beta-adrenergic stimulation. Bódi A; Szilágyi S; Edes I; Papp Z Gen Physiol Biophys; 2003 Sep; 22(3):313-27. PubMed ID: 14986883 [TBL] [Abstract][Full Text] [Related]
7. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure? Zimmermann N; Boknik P; Gams E; Herzig JW; Neumann J; Scholz H Eur J Cardiothorac Surg; 1998 Jul; 14(1):70-5. PubMed ID: 9726618 [TBL] [Abstract][Full Text] [Related]
8. The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts. Kristof E; Szigeti G; Papp Z; Bodi A; Ball NA; Walsh RA; Edes I Basic Res Cardiol; 1999 Aug; 94(4):223-30. PubMed ID: 10505421 [TBL] [Abstract][Full Text] [Related]
9. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Szilágyi S; Pollesello P; Levijoki J; Kaheinen P; Haikala H; Edes I; Papp Z Eur J Pharmacol; 2004 Feb; 486(1):67-74. PubMed ID: 14751410 [TBL] [Abstract][Full Text] [Related]
10. Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene. Hillestad V; Kramer F; Golz S; Knorr A; Andersson KB; Christensen G J Appl Physiol (1985); 2013 Nov; 115(10):1572-80. PubMed ID: 24072410 [TBL] [Abstract][Full Text] [Related]
11. Cardiac electrophysiological effects of levosimendan, a new calcium sensitizer. Virág L; Hála O; Marton A; Varró A; Papp JG Gen Pharmacol; 1996 Apr; 27(3):551-6. PubMed ID: 8723543 [TBL] [Abstract][Full Text] [Related]
12. Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. Szilágyi S; Pollesello P; Levijoki J; Haikala H; Bak I; Tósaki A; Borbély A; Edes I; Papp Z J Cardiovasc Pharmacol; 2005 Sep; 46(3):369-76. PubMed ID: 16116344 [TBL] [Abstract][Full Text] [Related]
13. Cardiotonic drugs differentially alter cytosolic [Ca2+] to left ventricular relationships before and after ischemia in isolated guinea pig hearts. Chen Q; Camara AK; Rhodes SS; Riess ML; Novalija E; Stowe DF Cardiovasc Res; 2003 Oct; 59(4):912-25. PubMed ID: 14553831 [TBL] [Abstract][Full Text] [Related]
14. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. Kaheinen P; Pollesello P; Levijoki J; Haikala H J Cardiovasc Pharmacol; 2004 Apr; 43(4):555-61. PubMed ID: 15085067 [TBL] [Abstract][Full Text] [Related]
16. Acute exposure to progesterone attenuates cardiac contraction by modifying myofilament calcium sensitivity in the female mouse heart. Feridooni HA; MacDonald JK; Ghimire A; Pyle WG; Howlett SE Am J Physiol Heart Circ Physiol; 2017 Jan; 312(1):H46-H59. PubMed ID: 27793852 [TBL] [Abstract][Full Text] [Related]
17. A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites. Asif M Mini Rev Med Chem; 2018; 18(16):1354-1362. PubMed ID: 27594341 [TBL] [Abstract][Full Text] [Related]
18. Levosimendan, a new inotropic and vasodilator agent. Toller WG; Stranz C Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404 [TBL] [Abstract][Full Text] [Related]
19. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Hasenfuss G; Pieske B; Castell M; Kretschmann B; Maier LS; Just H Circulation; 1998 Nov; 98(20):2141-7. PubMed ID: 9815868 [TBL] [Abstract][Full Text] [Related]
20. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium. Lochner A; Colesky F; Genade S Cardiovasc Drugs Ther; 2000 Jun; 14(3):271-81. PubMed ID: 10935149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]